Abstract | BACKGROUND: OBJECTIVE: We sought to evaluate the cutaneous response to oral sirolimus in patients with TSC and an indication for systemic treatment, including long-term effects. METHODS: A retrospective analysis of 14 adult patients with TSC prescribed sirolimus to treat lymphangioleiomyomatosis was performed. Serial photographs of angiofibromas, shagreen patches, and ungual fibromas taken before, during, and after the treatment period were blinded, then assessed using the Physician Global Assessment of Clinical Condition ( PGA). Microscopic and molecular studies were performed on skin tumors harvested before and during treatment. RESULTS:
Sirolimus significantly improved angiofibromas (median treatment duration 12 months; median PGA score 4.5 [range 1.5-5]; Wilcoxon signed rank test, P = .018) and shagreen patches (median treatment duration 10 months; median PGA score 4.5 [range 3.5-5]; Wilcoxon signed rank test, P = .039), whereas ungual fibromas improved in some patients (median treatment duration 6.5 months; median PGA score 4.66 [range 2.75-5]; Wilcoxon signed rank test, P = .109). Clinical, immunohistochemical, or molecular evidence of resistance was not observed (range 5-64 months of treatment). LIMITATIONS: CONCLUSION:
|
Authors | Neera Nathan, Ji-an Wang, Shaowei Li, Edward W Cowen, Mary Haughey, Joel Moss, Thomas N Darling |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 73
Issue 5
Pg. 802-8
(Nov 2015)
ISSN: 1097-6787 [Electronic] United States |
PMID | 26365597
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Published by Elsevier Inc. |
Chemical References |
- Antibiotics, Antineoplastic
- Ribosomal Protein S6
- Sirolimus
|
Topics |
- Acne Vulgaris
(chemically induced)
- Administration, Oral
- Adult
- Antibiotics, Antineoplastic
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Female
- Humans
- Middle Aged
- Oral Ulcer
(chemically induced)
- Retrospective Studies
- Ribosomal Protein S6
(analysis)
- Sirolimus
(administration & dosage, adverse effects)
- Skin Neoplasms
(drug therapy)
- Treatment Outcome
- Tuberous Sclerosis
(drug therapy)
|